CO4940401A1 - Vacunas - Google Patents

Vacunas

Info

Publication number
CO4940401A1
CO4940401A1 CO98032854A CO98032854A CO4940401A1 CO 4940401 A1 CO4940401 A1 CO 4940401A1 CO 98032854 A CO98032854 A CO 98032854A CO 98032854 A CO98032854 A CO 98032854A CO 4940401 A1 CO4940401 A1 CO 4940401A1
Authority
CO
Colombia
Prior art keywords
oil
water emulsion
adjuvant composition
stable
range
Prior art date
Application number
CO98032854A
Other languages
English (en)
Inventor
Nathalie Garcon
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO4940401A1 publication Critical patent/CO4940401A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición de un adyuvante, que comprende unaemulsión estable de aceite en agua en la que las gotitas de aceite tienen un diámetro medio en el intervalo de 300-600 nm.Una composición de un adyuvante, que comprende una emulsión estable de aceite en agua en la que la citada emulsión de aceite en agua comprende un aceite metabolizable y un triglicérido. Una composición de un adyuvante, que comprende una emulsión estable de aceite en agua en la que las gotitas de aceite tienen un diámetro medio en el intervalo de 300-600 nm, comprendiendo la citada emulsión de aceite en agua un aceite metabolizable y un triglicérido. Una composición de un adyuvante, que comprende una emulsión estable aceite en agua en la que las gotitas de aceite tiene un diámetro medio en el intervalo de 350-550 nm, comprendiendo la citada emulsión aceite en agua un aceite.1Un procedimiento para fabricar una vacuna de acuerdo con una cualquiera de las reivindicaciones 13 a 16, que comprende mezclar una emulsión de aceite en agua, tricaprilina, 3D-MPL,OS21, y un antígeno o preparación antigénica.
CO98032854A 1997-06-11 1998-06-09 Vacunas CO4940401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9711990.3A GB9711990D0 (en) 1997-06-11 1997-06-11 Vaccine

Publications (1)

Publication Number Publication Date
CO4940401A1 true CO4940401A1 (es) 2000-07-24

Family

ID=10813866

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98032854A CO4940401A1 (es) 1997-06-11 1998-06-09 Vacunas

Country Status (17)

Country Link
EP (1) EP0999852A1 (es)
JP (1) JP2002504106A (es)
KR (1) KR20010013644A (es)
CN (1) CN1260723A (es)
AR (1) AR012959A1 (es)
AU (1) AU728759B2 (es)
BR (1) BR9810614A (es)
CA (1) CA2293444A1 (es)
CO (1) CO4940401A1 (es)
GB (1) GB9711990D0 (es)
HU (1) HUP0004001A3 (es)
IL (1) IL133126A0 (es)
NO (1) NO996133L (es)
PL (1) PL337488A1 (es)
TR (1) TR199903048T2 (es)
WO (1) WO1998056414A1 (es)
ZA (1) ZA984969B (es)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
NZ515322A (en) * 1999-05-13 2004-03-26 Wyeth Corp Adjuvant combination formulations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
DK1227837T3 (da) 1999-10-22 2008-09-15 Aventis Pasteur Fremgangsmåde til introduktion og/eller fremskyndelse af et immunrespons på et tumorantigen
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
DE60131670T2 (de) 2000-10-18 2008-10-30 Glaxosmithkline Biologicals S.A. Impfstoffe gegen Krebskrankheiten
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2003022248A1 (en) * 2001-09-13 2003-03-20 Korea Institute Of Science And Technology Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
US20050250175A1 (en) * 2002-08-02 2005-11-10 Takehiko Nomura Bacterial cell wall skeleton component preparaion
WO2004037189A2 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
AU2005249212B2 (en) 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP1863529A1 (en) 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Novel composition
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DK2368572T3 (da) * 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
NO346529B1 (no) 2005-12-22 2022-09-26 Glaxosmithkline Biologicals Sa Bruk av et immunogenpreparat for småbarn, omfattende 22F sakkaridkonjugat
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI0710210A2 (pt) 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
EP2040743B1 (en) 2006-07-18 2013-10-02 GlaxoSmithKline Biologicals S.A. Vaccines for malaria
EP2040744B1 (en) 2006-07-25 2016-03-09 The Secretary of State for Defence Live vaccine strains of francisella
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
DK2068918T3 (da) 2006-09-26 2012-07-30 Infectious Disease Res Inst Vaccinesammensætning omfattende syntetisk adjuvant
KR101192127B1 (ko) 2006-11-03 2012-10-17 쉐링-프라우 리미티드 개 라임병 백신
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
CL2008002361A1 (es) 2007-08-13 2009-08-07 Glaxosmithkline Biologicals Sa Uso de un antigeno derivado de la proteina circumesporozoito (cs) de plasmodium falciparum que se expresa en la etapa preeritrocitica de la infeccion por malaria para tratar bebes contra la malaria.
PT2227483T (pt) 2007-12-19 2017-06-21 Henry M Jackson Found Advancement Military Medicine Inc Formas solúveis da glicoproteína f de vírus hendra e nipah e suas utilizações
CA2826508C (en) 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2349209A2 (en) 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
RU2560182C2 (ru) 2009-06-05 2015-08-20 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
JP6110140B2 (ja) 2009-06-16 2017-04-05 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ナノエマルションワクチン
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
AU2011231574A1 (en) 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US20130280322A1 (en) 2010-09-27 2013-10-24 Glaxosmithkline Biologicals S.A. Vaccine
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
AU2011335551B2 (en) 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EA034031B1 (ru) 2011-01-06 2019-12-20 Бионор Иммуно Ас Димерный пептид для индуцирования иммунного ответа против hiv и его применение
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
KR20140063825A (ko) 2011-09-16 2014-05-27 유씨비 파마, 에스.에이. 클로스트리듐 디피실의 주요 외독소 tcda 및 tcdb에 대한 중화 항체
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
WO2013083753A2 (en) 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
TR201908003T4 (tr) 2012-02-07 2019-06-21 Infectious Disease Res Inst TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
CN104619718A (zh) 2012-06-06 2015-05-13 比奥诺尔免疫有限公司 源自病毒蛋白的肽用作免疫原和配药成分
EP3932422A1 (en) 2012-07-24 2022-01-05 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
JP2015524422A (ja) 2012-07-24 2015-08-24 サノフィ・パスツールSanofipasteur ワクチン組成物
KR101819803B1 (ko) 2012-10-24 2018-01-17 플레이틀렛 타게티드 테라퓨틱스, 엘엘씨 혈소판 표적화 치료
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3063171B1 (en) 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
US10357554B2 (en) 2013-11-11 2019-07-23 The United States Of America, As Represented By The Secretary Of The Army AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
EP3068426B1 (en) 2013-11-13 2020-02-12 University Of Oslo Outer membrane vesicles and uses thereof
EP3069138B1 (en) 2013-11-15 2019-01-09 Oslo Universitetssykehus HF Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
EA201691028A1 (ru) 2013-11-20 2017-01-30 Ла Хойя Инститьют Фор Эллерджи Энд Иммьюнолоджи Пан-иммуногены пыльцы, способы и применение для модуляции иммунного ответа
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
SG11201605883UA (en) 2014-01-21 2016-08-30 Immune Design Corp Compositions for use in the treatment of allergic conditions
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
KR101696514B1 (ko) * 2014-08-18 2017-01-24 서울대학교산학협력단 신규한 온도 민감성 마이코박테리아 균주 및 이를 포함하는 마이코박테리아 감염증에 대한 백신 조성물
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
US11319383B2 (en) 2016-03-14 2022-05-03 Universitetet | Oslo Engineered immunoglobulins with altered FcRn binding
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
WO2018037045A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CA3066915A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
CN111315362A (zh) 2017-06-15 2020-06-19 传染病研究所 纳米结构脂质载剂和稳定乳剂以及其用途
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
JP2020533338A (ja) 2017-09-07 2020-11-19 ユニバーシティ オブ オスロUniversity of Oslo ワクチン分子
EP3703739A2 (en) 2017-11-03 2020-09-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
MX2020013553A (es) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
BR112021017584A2 (pt) 2019-03-05 2021-11-09 Glaxosmithkline Biologicals Sa Regime e composições de imunização contra hepatite b
AU2020283768A1 (en) 2019-05-25 2021-12-23 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
GB9711990D0 (en) 1997-08-06
CN1260723A (zh) 2000-07-19
PL337488A1 (en) 2000-08-28
BR9810614A (pt) 2000-09-12
AU728759B2 (en) 2001-01-18
HUP0004001A3 (en) 2001-07-30
NO996133D0 (no) 1999-12-10
IL133126A0 (en) 2001-03-19
TR199903048T2 (xx) 2000-08-21
HUP0004001A2 (en) 2001-03-28
AR012959A1 (es) 2000-11-22
ZA984969B (en) 1999-12-09
JP2002504106A (ja) 2002-02-05
AU8336598A (en) 1998-12-30
EP0999852A1 (en) 2000-05-17
CA2293444A1 (en) 1998-12-17
NO996133L (no) 2000-01-26
KR20010013644A (ko) 2001-02-26
WO1998056414A1 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
CO4940401A1 (es) Vacunas
ES2033626T3 (es) Formulacion de adyuvante que comprende una emulsion de gota de aceite submicronica.
BRPI0000126B8 (pt) composição de vacina, composição adjuvante e método de produção de uma composição de vacina
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
ES2175668T3 (es) Uso de microparticulas combinadas con emulsiones de aceite en agua submicronicas.
BR0100424A (pt) Nanoemulsão óleo-em-água que contém lipìdios anfìfilos e um polìmero não iÈnico, composição cosmética de uso tópico, suas utilizações, processo de tratamento não terapêutico e processo para espessar as nanoemulsões óleo-em -água
FI925835A (fi) Vacciner innehaollande liposomer
AR053833A1 (es) Composicion inmunogenetica
ES2167993T3 (es) Nanoemulsion a base de esteres grasos de glicerol, y sus utilizaciones en los ambitos cosmetico, dermatologico y/o oftalmologico.
TR199701713T1 (xx) Hepatit C a��lar�.
LU91486I2 (fr) Emulsion huile-dans-eau comprenant du squalène, duDL-a-tocophérol et du polysorbate 80
CY1108994T1 (el) Θερμοαναστρεψιμο ανοσοενισχυτικο γαλακτωμα
CY1106669T1 (el) Βελτιωμενο i mycoplasma hy opneumoniae/ i εμβολιο βακτηρινης
ES2059950T3 (es) Composicion de aceite o grasa emulsificada doble aceite-agua-aceite.
FR2710843B1 (fr) Composition d'organopolysiloxane d'aspect gélifié, sans gélifiant, utilisable en cosmétique et dermatologie.
EP1639988A3 (fr) Emulsion cosmétique eau-dans-huile solide
DE3855807D1 (de) Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
BR0107351A (pt) Composição perfumante sem álcool
NO972219D0 (no) Immunogenpreparater
DE60000223D1 (de) O/W-Emulsion enthaltende Fibern und ihre Verwendung in der Kosmetik
WO2002038176A3 (en) Immunogenic compositions comprising liver stage malarial antigens
ATE407564T1 (de) Zusammensetzung geeignet zur herstellung einer öl-in-wasser emulsion
WO1999002132A3 (en) Use of submicron oil-in-water emulsions with dna vaccines
AR015268A1 (es) Proceso para limpiar una alfombra.
BR0005882A (pt) lcoois de cadeia longa providos em óleos comestìveis